News

EzoneBio (Shanghai) Biotechnology Co., Ltd. recently rolled out its new-generation UV laser marking lineup, including the EZ-BM200 cassette printer and EZ-BP100 slide printer, featuring three core strengths: zero consumables, ultra-fast printing and full compatibility with lab information management systems. The EZ-BM200 tissue cassette printer adopts UV laser etching technology, requiring no ink or extra supplies. It finishes printing TXT/CSV files within 3 seconds, while PDF and image files take less than 5 seconds. Equipped with a 10-inch color touch screen, the device holds 6 detachable feed cassettes with a total input capacity of 480 tissue cassettes, and a large removable collection tray storing up to 120 cassettes for mass lab processing. Built-in barcode scanner supports texts, symbols, linear barcodes and QR codes. It seamlessly connects with mainstream LIMS and HIMS, working independently or matching slide printers to streamline lab workflows. The EZ-BP100 slide marker engraves marks directly on slides within 3 seconds. Laser-etched marks resist solvent erosion and avoid fading issues of traditional ink printing. Safety sensors monitor tray loading status to ensure daily operation safety. Industry insiders comment that UV laser marking equipment effectively cuts long-term lab operating costs and improves full sample traceability for pathological testing.

Chinese pathology equipment manufacturers are accelerating global expansion, with Chensi Biotechnology (Kunming) Co., Ltd. tapping markets across Southeast Asia, Europe and the United States. Chensi Bio plans overseas business to account for nearly 50% of its first-year revenue with annual growth exceeding 50%. The brand wins global clients via balanced reliable performance and competitive pricing without excessive brand premium. Three core strengths support its overseas layout. First, comprehensive product portfolio covering all steps of histology experiments for one-stop purchasing. Second, flexible customization services including OEM, ODM, private label packaging, specification adjustment and exclusive product sets for distributors. Third, full international service: English datasheets, export packaging, global logistics coordination and long-term stable supply guarantees. “Overseas labs and distributors prioritize stable supply and professional technical guidance,” said Chensi Bio’s international sales director. The team provides tailored product selection suggestions and accepts small trial orders for market testing. Industry observers note surging demand for cost-effective pathology instruments in emerging Southeast Asian markets, and Chinese manufacturers hold huge export potential. Chensi Bio’s overseas layout helps raise the global market share of China-made pathological lab products.

With booming biopharmaceutical R&D globally, pathology labs face troubles from multi-supplier coordination, inconsistent quality and high procurement costs. Chensi Biotechnology (Kunming) Co., Ltd. has launched an integrated full-process pathology solution to solve these challenges. The package covers three core business segments. First, complete pathology equipment: microtomes, tissue printers, flotation baths, slide dryers, embedding machines, stainers and tissue processors. Second, full-spectrum lab consumables & reagents, including cell culture supplies, molecular biology kits, histology stains, immunoassay kits and general lab disposables. Third, preclinical pathology CRO testing services supported by partner Ailian Bio (Hangzhou). “Traditional labs have to contact separate suppliers for devices, consumables and testing services, which brings heavy communication burdens,” said Chensi Bio’s management. Our one-stop system unifies quality standards and lowers overall procurement expenditure. Customized supply lists are available, and mainstream products can be shipped within 48 hours upon orders with cold-chain logistics for reagent safety. The CRO division provides H&E staining, special staining, IHC, IF, FISH, CISH, RNAscope and AI-aided tissue quantitative analysis. Regular projects take 7–15 working days, while urgent orders can be finished within 3–5 days. Market analysis shows integrated suppliers with equipment-consumable-service capability will gain greater competitive edges amid expanding domestic and overseas pathological testing demands.

Chensi Biotechnology (Kunming) Co., Ltd. unveiled its group strategic layout covering Kunming, Shanghai and Hangzhou, forming a complete industrial chain for pathology R&D, manufacturing, sales and technical services. Kunming headquarters takes charge of international sales and Southwest China market operation. Its branch EzoneBio (Shanghai) focuses on pathology equipment R&D and mass production, developing microtomes, laser markers, flotation baths and slide baking instruments. Ailian Bio (Hangzhou) specializes in preclinical pathology CRO testing, equipped with full Leica pathological devices and senior pathologist teams for strict quality control. The three locations share complementary advantages: Shanghai handles equipment development and production adaptation, Hangzhou delivers pathological technical verification, and Kunming integrates global supply chains and overseas market expansion. Relying on cross-regional technical collaboration, Chensi Bio identifies actual pain points in lab operations and converts practical demands into cost-effective, user-friendly pathology products. At present, its products cover over 30 domestic provinces, with core overseas markets in Southeast Asia, Europe and North America.

In April 2026, Chensi Biotechnology (Kunming) Co., Ltd. was formally established, together with its proprietary brand Censebio, committing to the R&D and international sales of pathology lab instruments, laboratory consumables and pathological reagents. Headquartered in Kunming, the company operates a 500 sq.m. manufacturing base in Medical Port Town, Qiantang District, Hangzhou. Supported by profound expertise in pathological preclinical research and lab instrument development, Chensi Bio integrates domestic supply chain resources to deliver products and solutions for global research institutes, pharmaceutical R&D enterprises, CROs, hospital pathology departments and third-party laboratories. “The founding of Censebio stems from long-term observation of real pain points in pathology labs,” a senior manager of Chensi Bio explained. The team found that imported premium equipment carries high purchase and maintenance costs, while many low-cost alternatives lack application verification and consistent technical after-sales support. Though China boasts a complete manufacturing system for pathology supplies, a trusted professional bridge linking high-quality domestic products and overseas buyers remains scarce. Guided by the core brand principle — “evaluate products with pathological expertise, upgrade products based on real lab demands”, Censebio builds a full-range product portfolio covering pathology instruments, histology consumables and general lab reagents. The company maintains strategic synergy with EzoneBio (Shanghai) and Ailian Bio (Hangzhou), offering flexible OEM, ODM and neutral private-label packaging services. The company targets an annual turnover of RMB 2 million in the first year, with overseas business accounting for around 50% of total revenue and a yearly growth rate of over 50%. Its products serve more than 30 provincial-level regions nationwide, alongside key overseas markets including Southeast Asia, Europe and the United States.